Usefulness and Limitations of Anti-S IgG Assay in Detecting Previous SARS-CoV-2 Breakthrough Infection in Fully Vaccinated Healthcare Workers

Usefulness and Limitations of Anti-S IgG Assay in Detecting Previous SARS-CoV-2 Breakthrough Infection in Fully Vaccinated Healthcare Workers

Introduction: The anti-spike (S) IgG assay is the most widely used method to assess the immunological response to COVID-19 vaccination. Several studies showed that subjects with perivaccination infection have higher anti-S IgG titers. However, a cut-off has not yet been identified so far for disting...

Full description

Bibliographic Details
Main Authors:	Gianluca Spiteri, Maria Grazia Lourdes Monaco, Gulser Caliskan, Angela Carta, Maria Diletta Pezzani, Giuseppe Lippi, Davide Gibellini, Giuseppe Verlato, Stefano Porru
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Series:	Diagnostics
Subjects:	SARS-CoV-2 vaccination SARS-CoV-2 breakthrough infection COVID-19 anti-S IgG healthcare workers
Online Access:	https://www.mdpi.com/2075-4418/12/9/2152

Similar Items

Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs
by: Tafadzwa Dzinamarira, et al.
Published: (2022-02-01)

SARS-CoV-2 and Its Variants in Thrice-Infected Health Workers: A Case Series from an Italian University Hospital
by: Maria Grazia Lourdes Monaco, et al.
Published: (2022-11-01)

Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
by: Chuancai Xu, et al.
Published: (2022-11-01)

COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany’s Largest Public Health Department (Cologne)
by: Lea Hsu, et al.
Published: (2021-11-01)

Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination
by: Hiroshi Kusunoki, et al.
Published: (2023-04-01)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
by: Thomas Perkmann, et al.
Published: (2023-08-01)

Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
by: Sharon Walmsley, et al.
Published: (2023-12-01)

Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions
by: Shi‐ting He, et al.
Published: (2022-12-01)

Evaluating the seroprevalence of SARS-CoV-2 IgG in five different districts of Bangladesh. A seroepidemiological study
by: Abdullah Al Saba, et al.
Published: (2023-06-01)

Risk Stratification of SARS-CoV-2 Breakthrough Infections Based on an Outbreak at a Student Festive Event
by: Ralph Bertram, et al.
Published: (2022-03-01)

COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective
by: Hiroshi Kusunoki
Published: (2023-06-01)

Trends in Antibody Titers after SARS-CoV-2 Vaccination—Insights from Self-Paid Tests at a General Internal Medicine Clinic
by: Hiroshi Kusunoki, et al.
Published: (2023-04-01)

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
by: Nungruthai Suntronwong, et al.
Published: (2022-03-01)

Primary and Recall Immune Responses to SARS-CoV-2 in Breakthrough Infection
by: Silvia D’Orso, et al.
Published: (2023-11-01)

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review
by: Qinglu Fan, et al.
Published: (2022-11-01)

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
by: Annapaola Santoro, et al.
Published: (2023-04-01)

SARS-CoV-2 Breakthrough Infections in Health Care Workers: An Italian Retrospective Cohort Study on Characteristics, Clinical Course and Outcomes
by: Luigi De Maria, et al.
Published: (2023-01-01)

SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
by: María Noel Badano, et al.
Published: (2023-02-01)

Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments
by: NICOLA SGHERZA, et al.
Published: (2024-02-01)

Neutralizing antibody levels detected early after mRNA-based vaccination do not predict by themselves subsequent breakthrough infections of SARS-CoV-2
by: Roberto Alonso, et al.
Published: (2024-02-01)

Can IgG Antibodies Directed against Different Targets Solve the Problem of False-Positive Results in SARS-CoV-2 Serology?
by: Nataša Beader, et al.
Published: (2021-01-01)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
by: Maren Bormann, et al.
Published: (2023-07-01)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination1
by: Hongyu Wang, et al.
Published: (2023-12-01)

An efficient ELISA protocol for measurement of SARS-CoV-2 spike-specific IgG in human plasma and serum samples
by: Gwenllian A. Appeltrath, et al.
Published: (2024-06-01)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
by: Berthold Hocher, et al.
Published: (2022-10-01)

SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers
by: Stefano Porru, et al.
Published: (2022-07-01)

In Silico Design of Peptide-Based SARS-CoV-2 Fusion Inhibitors That Target WT and Mutant Versions of SARS-CoV-2 HR1 Domains
by: Shana V. Stoddard, et al.
Published: (2021-07-01)

A Microflow Cytometry-Based Agglutination Immunoassay for Point-of-Care Quantitative Detection of SARS-CoV-2 IgM and IgG
by: Jianxi Qu, et al.
Published: (2021-04-01)

Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review
by: Shilpa Gopinath, et al.
Published: (2022-05-01)

Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19
by: Chan Mi Lee, et al.
Published: (2023-03-01)

Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age
by: Margarethe Konik, et al.
Published: (2021-10-01)

Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus
by: Ioannis Mamais, et al.
Published: (2021-12-01)

Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections
by: Yun Shan Goh, et al.
Published: (2022-11-01)

Memory SARS-CoV-2 T-cell response in convalescent COVID-19 patients with undetectable specific IgG antibodies: a comparative study
by: Raquel Fernández-Moreno, et al.
Published: (2023-04-01)

Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
by: Carla Martín Pérez, et al.
Published: (2024-03-01)

Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination
by: Matthaios Speletas, et al.
Published: (2023-12-01)

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
by: Arne Søraas, et al.
Published: (2022-09-01)

Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic
by: Donald J. Alcendor, et al.
Published: (2022-05-01)

Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort Survey
by: Stefano Porru, et al.
Published: (2022-02-01)

Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review
by: Ridhima Kaul, et al.
Published: (2021-10-01)